This clinical trial aims to evaluate the effectiveness of a pharmacist-led counseling and self-management application program on improving asthma management outcomes among adult patients with asthma receiving care at a Midwest chain pharmacy in Iowa, United States.

The study investigates whether integrating the pharmacist counseling with self-management theory can enhance patients' medication adherence, asthma control, inhaler technique, and overall asthma awareness. These outcomes will be assessed at both 3 and 6 months after enrollment.

Participants will be randomly assigned to one of two arms. The intervention group, which will receive a comprehensive pharmacist-led counseling program supported by a mobile application ("Don R.Ph Application").

The control group, which will receive standard pharmacy care as per usual practice.

Protocol of the Study This research employs a randomized controlled trial (RCT) methodology to evaluate the effectiveness of a pharmacist-led counseling and self-management application program for asthma management.

Study Design:

This is a 6-month, repeated-measures, parallel-group RCT designed to assess the intervention's impact on asthma outcomes. The study comprises two groups:

Intervention Group: Participants will receive a pharmacist-led counseling session combined with access to a self-management mobile application.

Control Group: Participants will receive usual care provided within the pharmacy setting.

Data Collection Process:

1. Screening: Eligible participants will be identified based on predefined inclusion and exclusion criteria.
2. Randomization and Blinding: After screening, eligible participants will be randomly assigned to either the intervention or control group in a single-blind manner.

Sample Size and Allocation:

• A total of 397 patients with asthma diagnosis codes will be initially screened for eligibility.
• Among these, 220 patients meeting the criteria will be assigned unique codes and recorded in Microsoft Excel.

Using simple randomization, 42 participants will be allocated to each group, maintaining a 1:1 ratio via computerized random number generation (using the RANDBETWEEN function in Excel) to minimize selection bias.

4. Informed Consent: Participants will be provided with detailed study information and will give written informed consent prior to participation.

5. Baseline Data Collection: Baseline demographic and clinical data will be gathered for all participants in both groups.

6. Interventions:

• Intervention Group: Participants will undergo a structured pharmacist-led counseling and self-management program utilizing the "Don R.Ph. Asthma Management Application," a digital tool designed to support and monitor asthma management through six core steps over two 3-month cycles.

• Control Group: Participants will receive standard pharmacy care, including medication reviews, patient education, and counseling on medication use as needed or upon request.

  7. Follow-up and Duration: Follow-up data will be collected at three and six months during and after the intervention period.

The study spans six months, with the intervention structured into six steps:

Month 1:

Step 1: Initial Disclosure Step 2: Problem Assessment Step 3: Commitment to Action Step 4: Skill Enhancement

Month 2:

Step 5: Monitoring via mobile application

Month 3:

Step 6: Follow-up and evaluation via mobile app and in-person counseling

This cycle will be repeated in months 4-6 to reinforce behavioral changes and optimize long-term outcomes.

The "Don R.Ph. Asthma Management Application" is a digital platform to support and monitor the pharmacist-led counseling process through eight key features:

1. Setting Your Goal! - Enables patients to establish personalized asthma management objectives.
2. Understanding Asthma - Offers educational videos about asthma and proper medication use.
3. How to Use Inhalers - Demonstrates correct inhaler techniques via videos.
4. Healthy Lifestyle - Shares practical tips to promote overall health and asthma control.
5. Asthma Self-Management & Action Plan - Guides patients in creating and following tailored action plans.
6. Automated Consultation - Provides automated, personalized guidance and reminders
7. Let Us Know - Offers quick access to emergency pharmacist contact for urgent concerns.
8. Assess Your Goal Achievement - Allows patients to monitor their progress toward management goals through self-assessment tools.

Inclusion criteria:

1. Adult patients with asthma are 25 - 64 years of age.
2. Have been receiving medications from the pharmacy of either Inhaled Corticosteroids (ICS) or a fixed combination of ICS with a long-acting beta-agonist (bronchodilator) and regular patronage of the pharmacy for the previous six months.
3. Confirmed diagnosis from either the physician's diagnosis or the patient's self-report.
4. No respiratory comorbidities (i.e., COPD or lung diseases).
5. Uses a smartphone (IOS or Android).
6. Ability to communicate with the pharmacist in English.
7. Volunteer to participate in the program for the period.

Exclusion criteria:

1. The adult patient with asthma aged < 25 years or > 64 years old.
2. The patient with one of the following - coronary heart disease, severe hypertension, severe heart failure, severe musculoskeletal disorder, mental health condition, dementia, chronic obstructive lung disease, or COVID-19.
3. Participating in another "Pharmacy Counseling or Education Program."
4. The patient does not have a smartphone (iOS or Android).
5. The patient does not have sufficient comprehension or the ability to communicate effectively in English.
6. The patient is unwilling or unable to participate in the entire program.

1. De-identified individual participant data related to the study's primary and secondary outcomes, including data on medication adherence, asthma control scores, inhaler technique performance, and asthma awareness assessments.
2. Study protocol, statistical analysis plan, and informed consent form (de-identified and redacted as appropriate).

1. Data will be made available beginning 6 months after publication of the primary study results, or 12 months after the completion of the trial, whichever occurs first.
2. The data will be available for at least 5 years following its release.

Qualified researchers affiliated with academic institutions, public health organizations, or non-profit entities.

Outcome assessors and data analysts will be blinded to group assignments to minimize bias during data collection and statistical analysis. The researcher will not be blinded due to the nature of usual care.